Altered serum levels of insulin-like growth-factor binding proteins in breast cancer patients

1998 ◽  
Vol 5 (2) ◽  
pp. 194-201 ◽  
Author(s):  
Eng-Hen Ng ◽  
Chen-Yang Ji ◽  
Puay-Hoon Tan ◽  
Valerie Lin ◽  
Khee-Chee Soo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Cancer Patients ◽  
Binding Proteins ◽  
Serum Levels ◽  
Insulin Like Growth Factor ◽  
Breast Cancer Patients ◽  
Factor Binding ◽  
Altered Serum

Significant Changes in Circulating Plasma Levels of IGF1 and IGFBP3 after Conventional or Dose-Intensified Adjuvant Treatment of Breast Cancer Patients with one to three Positive Lymph Nodes

2007 ◽  
Vol 22 (3) ◽  
pp. 186-193 ◽  
Author(s):  
S. Kümmel ◽  
H. Eggemann ◽  
D. Lüftner ◽  
N. Gebauer ◽  
H. Bühler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Adjuvant Chemotherapy ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Plasma Levels ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
Breast Cancer Patients ◽  
Positive Lymph Nodes

The insulin-like growth factor 1 (IGF1) and its binding protein IGFBP3 (insulin-like growth factor binding protein 3) play a pivotal role during the growth and development of tissues. The purpose of this study was to evaluate the influence of anthracycline- and taxane-containing adjuvant chemotherapy in breast cancer patients on the circulating plasma levels of IGF1 and its main binding protein, IGFBP3. This investigation was part of a prospective randomized phase III study in which breast cancer patients were treated with either conventional or dose-intensified adjuvant chemotherapy. The factors were quantified in the plasma of 151 patients with a commercially available sandwich enzyme immunoassay. Before therapy, both parameters were within the normal range in most patients (n=145 and n=144). After therapy, both factors had increased significantly by 29% (IGF1) and 19% (IGFBP3), with the highest increase being observed in the dose-intensified group. Correlations with patient and tumor characteristics revealed a relatively higher increase in both parameters in premenopausal patients, patients with lower-grade tumors, more positive lymph nodes, larger tumor volume, and positive hormone receptor status. No correlation was found with the HER2 expression of the tumors.

Sign in / Sign up

Export Citation Format

Share Document